COLA: Atopic Dermatitis
Session recorded on August 25, 2017.
Speaker: Luz Fonacier, MD
Viewers can earn credit by completing the posttest questions.
Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease that affects children and adults. Patients with moderate-to-severe AD often receive little benefit from current treatment therapies. The only FDA-approved systemic treatment option for these patients is systemic steroids. Second line therapy for AD (not yet approved by the FDA) includes a host of immunosuppressants, which are not indicated for AD and may have serious adverse effects. New research on the immune pathogenesis of AD has paved the way for new, targeted, systemic therapies for AD; clinicians need help integrating these new therapies into current treatment paradigms. This video covers the pathogenesis of AD, the associated features, how to determine disease severity, the biomarkers, the triggers, and the therapeutic options of AD.
Practicing Allergists / Immunologists
After viewing the video recording, learners should be able to…
- Identify common "mimics" of AD
- Discuss the workup of AD
- Discuss treatments of AD
Luz Fonacier, MD
Professor of Clinical Medicine
SUNY at Stony Brook
Section Head of Allergy
Training Program Director
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no commercial support for this activity.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance